October 10, 2025 | Mary Kohler for Bloomberg Law Sarepta's Elevidys crisis tested not just science but leadership. It offers a rare look at how a small biotech's stakeholders—and risk profile—can differ from the compliance frameworks of larger players. Attorney Mary Kohler explains how thoughtful decisions can help emerging companies withstand scrutiny when their own moment arrives. Sarepta Therapeutics found itself in turmoil after patient deaths raised safety question

Attorney Mary Kohler breaks down Texas v. Lilly into ten things health lawyers and biopharma leaders need to know. From the “free work” theory to state AG activism, this article explains why this case matters and what it could mean for manufacturers, providers and patients.

July 11, 2025 | By Mary Kohler in Bloomberg Law Life sciences attorney Mary Kohler says boards with standalone risk committees...

Kohler Health Law is honored to be recognized by Chambers and Partners USA: Spotlight Guide 2025 for excellence in Healthcare Law in California.

February 13, 2025 | By Mary Kohler in Law360 Last year ushered in new Anti-Kickback Statute concerns for biopharma companies after...